These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25673120)

  • 61. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection.
    Ludlow CL; Naunton RF; Terada S; Anderson BJ
    Otolaryngol Head Neck Surg; 1991 Jun; 104(6):849-55. PubMed ID: 1908979
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adductor muscle activity abnormalities in abductor spasmodic dysphonia.
    Cyrus CB; Bielamowicz S; Evans FJ; Ludlow CL
    Otolaryngol Head Neck Surg; 2001 Jan; 124(1):23-30. PubMed ID: 11228447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
    Zwirner P; Murry T; Swenson M; Woodson GE
    Laryngoscope; 1992 Apr; 102(4):400-6. PubMed ID: 1556889
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact in vocal quality in partial myectomy and neurectomy endoscopic of thyroarytenoid muscle in patients with adductor spasmodic dysphonia.
    Tsuji DH; Chrispim FS; Imamura R; Sennes LU; Hachiya A
    Braz J Otorhinolaryngol; 2006; 72(2):261-6. PubMed ID: 16951863
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Partial thyroarytenoid myectomy: an animal study investigating a proposed new treatment for adductor spasmodic dysphonia.
    Genack SH; Woo P; Colton RH; Goyette D
    Otolaryngol Head Neck Surg; 1993 Mar; 108(3):256-64. PubMed ID: 8464639
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
    Murry T; Woodson GE
    J Voice; 1995 Dec; 9(4):460-5. PubMed ID: 8574315
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia.
    Fritzell B; Hammarberg B; Schiratzki H; Haglund S; Knutsson E; Mårtensson A
    J Voice; 1993 Jun; 7(2):172-8. PubMed ID: 8353632
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
    Morzaria S; Damrose EJ
    J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bilateral thyroarytenoid denervation: a new treatment for laryngeal hyperadduction disorders studied in the canine.
    Sercarz JA; Berke GS; Ming Y; Rothschiller J; Graves MC
    Otolaryngol Head Neck Surg; 1992 Nov; 107(5):657-68. PubMed ID: 1437204
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series.
    Blitzer A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():28-30. PubMed ID: 20590805
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current practices in the management of adductor spasmodic dysphonia.
    Eskander A; Fung K; McBride S; Hogikyan N
    J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term follow-up of recurrent laryngeal nerve avulsion for the treatment of spastic dysphonia.
    Weed DT; Jewett BS; Rainey C; Zealear DL; Stone RE; Ossoff RH; Netterville JL
    Ann Otol Rhinol Laryngol; 1996 Aug; 105(8):592-601. PubMed ID: 8712628
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture.
    Crevier-Buchman L; Laccourreye O; Papon JF; Nurit D; Brasnu D
    J Voice; 1997 Jun; 11(2):232-7. PubMed ID: 9181547
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Practice parameter: laryngeal electromyography (an evidence-based review).
    Sataloff RT; Mandel S; Mann EA; Ludlow CL
    J Voice; 2004 Jun; 18(2):261-74. PubMed ID: 15193662
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diagnosis of unilateral recurrent laryngeal nerve paralysis: laryngeal electromyography, subjective rating scales, acoustic and aerodynamic measures.
    Bielamowicz S; Stager SV
    Laryngoscope; 2006 Mar; 116(3):359-64. PubMed ID: 16540889
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vocal outcome after endoscopic thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia.
    Gandhi S; Remacle M; Mishra P; Desai V
    Eur Arch Otorhinolaryngol; 2014 Dec; 271(12):3249-54. PubMed ID: 24920326
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series.
    Payne S; Tisch S; Cole I; Brake H; Rough J; Darveniza P
    Mov Disord; 2014 May; 29(6):729-35. PubMed ID: 24753288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.